Teva Pharmaceutical Industries Stock Forecast for 2023 - 2025 - 2030
Updated on 05/21/2024
Teva Pharmaceutical Industries Stock Forecast and Price Target
The average target price set lately by nine experts for Teva Pharmaceutical Industries to reach by the end of the year is $17.00, which would imply a potential upside of approximately 1.13 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $20.00 and a low estimate of $14.50. If you're looking to buy Teva Pharmaceutical Industries stock, you may also want to check out its rivals.
1.13% Upside
Teva Pharmaceutical Industries Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Teva Pharmaceutical Industries's Price has gone down from $9.33 to $0.00 – a 100.00% drop. In the next year, analysts expect Fair Value to reach $8.78 – an increase of 100.00%. For the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$783.18 | Buy/Sell | $636.99 | 12.04% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$151.27 | Buy/Sell | $174.55 | 12.38% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.99 | Buy/Sell | $130.51 | 9.17% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.56 | Buy/Sell | $178.42 | 10.90% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.96 | Buy/Sell | £165.99 | 34.80% |
Teva Pharmaceutical Industries Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Teva Pharmaceutical Industries's Revenue has gone down from $16.66B to $15.85B – a 4.88% drop. In the next year, 10 analysts estimate that Teva Pharmaceutical Industries's Revenue will decrease by 2.89%, reaching $15.39B. For the next eight years, the forecast is for Revenue to grow by 26.94%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$103.21 | Buy/Sell | $118.92 | 22.57% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$314.54 | Buy/Sell | $303.65 | 1.74% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.75 | Buy/Sell | £17.30 | 12.39% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$43.36 | Buy/Sell | $58.15 | 24.54% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.90 | Buy/Sell | $87.82 | 17.82% |
| MRK Stock Forecast | Merck KGaA | Outperform |
18
|
166.55€ | Buy/Sell | 190.06€ | 9.88% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
10
|
$105.21 | Buy/Sell | $109.39 | -1.63% |
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF80.08 | Buy/Sell | CHF90.64 | 20.97% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF529.20 | Buy/Sell | CHF516.89 | 13.38% |
Teva Pharmaceutical Industries EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Teva Pharmaceutical Industries's EBITDA has decreased by 6.05%, going from $4.61B to $4.33B. Next year, analysts are expecting EBITDA to reach $4.70B – an increase of 8.44%. Over the next eight years, the forecast is for EBITDA to grow by 35.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DSFIR Stock Forecast | DSM-Firmenich | Outperform |
18
|
108.15€ | Buy/Sell | 114.60€ | 10.96% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.67€ | Buy/Sell | 45.15€ | 4.64% |
| PHIA Stock Forecast | Koninklijke Philips N.V. | Hold |
18
|
25.40€ | Buy/Sell | 19.42€ | -4.84% |
Teva Pharmaceutical Industries EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Teva Pharmaceutical Industries's EBIT has grown by 4.09%, rising from $3.06B to $3.18B. For next year, analysts predict EBIT of $4.19B, which would mean an increase of 31.65%. Over the next nine years, experts predict that Teva Pharmaceutical Industries's EBIT will grow at a rate of 17.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr2.04k | Buy/Sell | kr2.71k | 29.35% |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
27.75€ | Buy/Sell | 38.63€ | 27.93% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.51k | Buy/Sell | ¥2.64k | 32.32% |
Teva Pharmaceutical Industries EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Teva Pharmaceutical Industries's EPS has gone down from $2.57 to $0.00 – a 100.00% drop. In the next year, analysts expect EPS to reach $2.42 – an increase of 100.00%. For the next eight years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NBIX Stock Forecast | Neurocrine Biosciences | Outperform |
16
|
$141.65 | Buy/Sell | $138.03 | 11.90% |
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.40k | Buy/Sell | Rp1.43k | 9.72% |
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.66k | Buy/Sell | ¥9.58k | 26.22% |
Site Navigation
.jpg)